Welcome
Support Centre
11 October 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A Randomised Trial of Adriamycin and Taxotere vs. Adriamycin and Cyclophosphamide in Breast Cancer
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN15113276
Date ISRCTN assigned19/08/2002
Local reference number(s)BR 9809
Public titleA Randomised Trial of Adriamycin and Taxotere vs. Adriamycin and Cyclophosphamide in Breast Cancer
Scientific title
AcronymN/A
Disease/condition/study domainBreast cancer
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Histologically proven breast cancer
2. Potentially operable disease >3cm diameter, locally advanced disease (including T4 lesions) or inflammatory BrCa
3. Patients older then 18 years
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated start date01/07/1999
Anticipated end date01/07/2002
Status of trialCompleted
Target number of participantsNot provided at time of registration
Interventions1. Adriamycin 50 mg/m^2 intravenous (iv) 3 weekly + taxotere 75 mg/m^2 iv 3 weekly (NB Taxotere must be administered prior to Adriamycin)

2. Adriamycin (60 mg/m^2 iv) 3 weekly + cyclophosphamide (600 mg/m^2 iv) weekly. Maximum of 6 cycles of combination chemotherapy.
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingScottish Therapy Network
Sponsor nameScottish Cancer Therapy Network
Sponsor detailsTrinity Park House
South Trinity Road
Edinburgh
United Kingdom
EH5 3SQ
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN15113276
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central